Approximately 50% of cancer patients develop anemia. In the past, the only available treatment option for these patients was transfusion. Since the late 1980s, recombinant human erythropoietin (rHuEPO, epoetin alfa
Ivor Cavill, PhD
Advertisement
Articles by Ivor Cavill, PhD
Advertisement
Latest Updated Articles
- Role of Iron in Optimizing Responses of Anemic Cancer Patients to Erythropoietin
Published: April 1st 1999 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Sac-TMT Combo Produces Encouraging Activity in Pretreated Metastatic CRPC
2
Zurletrectinib Generates Responses in Advanced NTRK Fusion Solid Tumors
3
FDA Grants Interchangeability Designation to 2 Denosumab Biosimilars
4
Molecular Insights Into Cancer Cachexia: An Evolution in Identifying the Syndrome
5
